The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy

References

• Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722–728.
   PubMed Web of Science ®Google Scholar
• Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore). 2006;85:193–202.
   PubMed Web of Science ®Google Scholar
• Howard V, Greene JM, Pahwa S, et al. The health status and quality of life of adults with X-linked agammaglobulinemia. Clin Immunol. 2006;118:201–208.
   PubMed Web of Science ®Google Scholar
• Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226–233.
   PubMed Web of Science ®Google Scholar
• Tsukada S, Saffran DC, Rawlings DJ, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72:279–290.
   PubMed Web of Science ®Google Scholar
• Thomas JD, Sideras P, Smith CI, et al. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science. 1993;261:355–358.
   PubMed Web of Science ®Google Scholar
• Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of Bruton’s tyrosine kinase in immunodeficient XID mice. Science. 1993;261:358–361.
   PubMed Web of Science ®Google Scholar
• Khan WN, Sideras P, Rosen FS, et al. The role of Bruton’s tyrosine kinase in B-cell development and function in mice and man. Ann NY Acad Sci. 1995;764:27–38.
   PubMed Web of Science ®Google Scholar
• Jansson L, Holmdahl R. Genes on the X chromosome affect development of collagen-induced arthritis in mice. Clin Exp Immunol. 1993;94:459–465.
   PubMed Web of Science ®Google Scholar
• Khan WN, Alt FW, Gerstein RM, et al. Defective B cell development and function in Btk-deficient mice. Immunity. 1995;3:283–299.
   PubMed Web of Science ®Google Scholar
• Middendorp S, Dingjan GM, Maas A, et al. Function of Bruton’s tyrosine kinase during B cell development is partially independent of its catalytic activity. J Immunol. 2003;171:5988–5996.
   PubMed Web of Science ®Google Scholar
• Middendorp S, Zijlstra AJ, Kersseboom R, et al. Tumor suppressor function of Bruton tyrosine kinase is independent of its catalytic activity. Blood. 2005;105:259–265.
   PubMed Web of Science ®Google Scholar
• Sideras P, Muller S, Shiels H, et al. Genomic organization of mouse and human Bruton’s agammaglobulinemia tyrosine kinase (Btk) loci. J Immunol. 1994;153:5607–5617.
   PubMed Web of Science ®Google Scholar
• Petro JB, Rahman SM, Ballard DW, et al. Bruton’s tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J Exp Med. 2000;191:1745–1754.
   PubMed Web of Science ®Google Scholar
• Petro JB, Khan WN. Phospholipase C-gamma 2 couples Bruton’s tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes. J Biol Chem. 2001;276:1715–1719.
   PubMed Web of Science ®Google Scholar
• Saffran DC, Parolini O, Fitch-Hilgenberg ME, et al. Brief report: a point mutation in the SH2 domain of Bruton’s tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med. 1994;330:1488–1491.
   PubMed Web of Science ®Google Scholar
• Rawlings DJ, Scharenberg AM, Park H, et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science. 1996;271:822–825.
   PubMed Web of Science ®Google Scholar
• Kelly V, Genovese M. Novel small molecule therapeutics in rheumatoid arthritis. Rheumatology. 2013;52:1155–1162.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.
   PubMed Web of Science ®Google Scholar
• Mina-Osorio P, LaStant J, Keirstead N, et al. Suppression of glomerulonephritis in lupus-prone NZB x NZW mice by RN486, a selective inhibitor of Bruton’s tyrosine kinase. Arthritis Rheum. 2013;65:2380–2391.
   PubMed Web of Science ®Google Scholar
• Burger JA. Bruton’s tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 2014;9:44–49.
   PubMed Web of Science ®Google Scholar
• Saito K, Tolias KF, Saci A, et al. BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity. Immunity. 2003;19:669–678.
   PubMed Web of Science ®Google Scholar
• Whyburn LR, Halcomb KE, Contreras CM, et al. Reduced dosage of Bruton’s tyrosine kinase uncouples B cell hyperresponsiveness from autoimmunity in lyn-/- mice. J Immunol. 2003;171:1850–1858.
   PubMed Web of Science ®Google Scholar
• Satterthwaite AB, Cheroutre H, Khan WN, et al. Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc Natl Acad Sci U S A. 1997;94:13152–13157.
   PubMed Web of Science ®Google Scholar
• Kil LP, de Bruijn MJW, van Nimwegen M, et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood. 2012;119:3744–3756.
   PubMed Web of Science ®Google Scholar
• Bonami RH, Sullivan AM, Case JB, et al. Bruton’s tyrosine kinase promotes persistence of mature anti-insulin B cells. J Immunol. 2014;192:1459–1470.
   PubMed Web of Science ®Google Scholar
• Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374–1377.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Terrier B, Bannock J, et al. Expansion of autoreactive unresponsive CD21-/low B cells in Sjogren’s syndrome-associated lymphoproliferation. Arthritis Rheum. 2013;65:1085–1096.
   PubMed Web of Science ®Google Scholar
• Kinnunen T, Chamberlain N, Morbach H, et al. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest. 2013;123:2737–2741.
   PubMed Web of Science ®Google Scholar
• Quach TD, Manjarrez-Orduno N, Adlowitz DG, et al. Anergic responses characterize a large fraction of human autoreactive naive B cells expressing low levels of surface IgM. J Immunol. 2011;186:4640–4648.
   PubMed Web of Science ®Google Scholar
• Serreze DV, Fleming SA, Chapman HD, et al. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol. 1998;161:3912–3918.
   PubMed Web of Science ®Google Scholar
• Noorchashm H, Lieu YK, Noorchashm N, et al. I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. J Immunol. 1999;163:743–750.
   PubMed Web of Science ®Google Scholar
• Kendall PL, Case JB, Sullivan AM, et al. Tolerant anti-insulin B cells are effective APCs. J Immunol. 2013;190:2519–2526.
   PubMed Web of Science ®Google Scholar
• Kalampokis I, Yoshizaki A, Tedder TF. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther. 2013;15 Suppl 1:S1.
   PubMed Web of Science ®Google Scholar
• Kendall PL, Woodward EJ, Hulbert C, et al. Peritoneal B cells govern the outcome of diabetes in non-obese diabetic mice. Eur J Immunol. 2004;34:2387–2395.
   PubMed Web of Science ®Google Scholar
• Kendall PL, Yu G, Woodward EJ, et al. Tertiary lymphoid structures in the pancreas promote selection of B lymphocytes in autoimmune diabetes. J Immunol. 2007;178:5643–5651.
   PubMed Web of Science ®Google Scholar
• Kendall PL, Moore DJ, Hulbert C, et al. Reduced diabetes in btk-deficient nonobese diabetic mice and restoration of diabetes with provision of an anti-insulin IgH chain transgene. J Immunol. 2009;183:6403–6412.
   PubMed Web of Science ®Google Scholar
• Halcomb KE, Musuka S, Gutierrez T, et al. Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells. Mol Immunol. 2008;46:233–241.
   PubMed Web of Science ®Google Scholar
• Flaswinkel H, Reth M. Dual role of the tyrosine activation motif of the Ig-alpha protein during signal transduction via the B cell antigen receptor. EMBO J. 1994;13:83–89.
   PubMed Web of Science ®Google Scholar
• Rowley RB, Burkhardt AL, Chao HG, et al. Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Ig alpha/Ig beta immunoreceptor tyrosine activation motif binding and autophosphorylation. J Biol Chem. 1995;270:11590–11594.
   PubMed Web of Science ®Google Scholar
• Corneth OBJ, Klein Wolterink RGJ, Hendriks RW. BTK signaling in B cell differentiation and autoimmunity. Curr Top Microbiol Immunol. 2016;393:67–105.
   PubMed Web of Science ®Google Scholar
• Hendriks RW, de Bruijn MF, Maas A, et al. Inactivation of Btk by insertion of lacZ reveals defects in B cell development only past the pre-B cell stage. EMBO J. 1996;15:4862–4872.
   PubMed Web of Science ®Google Scholar
• Kerner JD, Appleby MW, Mohr RN, et al. Impaired expansion of mouse B cell progenitors lacking Btk. Immunity. 1995;3:301–312.
   PubMed Web of Science ®Google Scholar
• Baba Y, Hashimoto S, Matsushita M, et al. BLNK mediates Syk-dependent Btk activation. Proc Natl Acad Sci U S A. 2001;98:2582–2586.
   PubMed Web of Science ®Google Scholar
• Kurosaki T, Kurosaki M. Transphosphorylation of Bruton’s tyrosine kinase on tyrosine 551 is critical for B cell antigen receptor function. J Biol Chem. 1997;272:15595–15598.
   PubMed Web of Science ®Google Scholar
• Morrogh LM, Hinshelwood S, Costello P, et al. The SH3 domain of Bruton’s tyrosine kinase displays altered ligand binding properties when auto-phosphorylated in vitro. Eur J Immunol. 1999;29:2269–2279.
   PubMed Web of Science ®Google Scholar
• Guo S, Ferl GZ, Deora R, et al. A phosphorylation site in Bruton’s tyrosine kinase selectively regulates B cell calcium signaling efficiency by altering phospholipase C-gamma activation. Proc Natl Acad Sci U S A. 2004;101:14180–14185.
   PubMed Web of Science ®Google Scholar
• Hashimoto A, Okada H, Jiang A, et al. Involvement of guanosine triphosphatases and phospholipase C-gamma2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor. J Exp Med. 1998;188:1287–1295.
   PubMed Web of Science ®Google Scholar
• Khan WN. Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase. Immunol Res. 2001;23:147–156.
   PubMed Web of Science ®Google Scholar
• Antony P, Petro JB, Carlesso G, et al. B cell receptor directs the activation of NFAT and NF-kappaB via distinct molecular mechanisms. Exp Cell Res. 2003;291:11–24.
   PubMed Web of Science ®Google Scholar
• Jongstra-Bilen J, Puig Cano A, Hasija M, et al. Dual functions of Bruton’s tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis. J Immunol. 2008;181:288–298.
   PubMed Web of Science ®Google Scholar
• Paracha RZ, Ali A, Ahmad J, et al. Structural evaluation of BTK and PKCδ mediated phosphorylation of MAL at positions Tyr86 and Tyr106. Comput Biol Chem. 2014;51:22–35.
   PubMed Web of Science ®Google Scholar
• Hartkamp LM, Fine JS, van Es IE, et al. Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants. Ann Rheum Dis. 2015;74:1603–1611.
   PubMed Web of Science ®Google Scholar
• Dal Porto JM, Gauld SB, Merrell KT, et al. B cell antigen receptor signaling 101. Mol Immunol. 2004;41:599–613.
   PubMed Web of Science ®Google Scholar
• Hyvonen M, Saraste M. Structure of the PH domain and Btk motif from Bruton’s tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia. EMBO J. 1997;16:3396–3404.
   PubMed Web of Science ®Google Scholar
• Hansson H, Mattsson PT, Allard P, et al. Solution structure of the SH3 domain from Bruton’s tyrosine kinase. Biochemistry. 1998;37:2912–2924.
   PubMed Web of Science ®Google Scholar
• Huang KC, Cheng HT, Pai MT, et al. Solution structure and phosphopeptide binding of the SH2 domain from the human Bruton’s tyrosine kinase. J Biomol NMR. 2006;36:73–78.
   PubMed Web of Science ®Google Scholar
• Mao C, Zhou M, Uckun FM. Crystal structure of Bruton’s tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J Biol Chem. 2001;276:41435–41443.
   PubMed Web of Science ®Google Scholar
• Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 1997;90:1073–1083.
   PubMed Web of Science ®Google Scholar
• Turner M, Mee PJ, Costello PS, et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature. 1995;378:298–302.
   PubMed Web of Science ®Google Scholar
• Kitamura D, Roes J, Kuhn R, et al. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature. 1991;350:423–426.
   PubMed Web of Science ®Google Scholar
• Kersseboom R, Kil L, Flierman R, et al. Constitutive activation of Bruton’s tyrosine kinase induces the formation of autoreactive IgM plasma cells. Eur J Immunol. 2010;40:2643–2654.
   PubMed Web of Science ®Google Scholar
• Llorente L, Zou W, Levy Y, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med. 1995;181:839–844.
   PubMed Web of Science ®Google Scholar
• Ishida H, Muchamuel T, Sakaguchi S, et al. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med. 1994;179:305–310.
   PubMed Web of Science ®Google Scholar
• Valiaho J, Smith CI, Vihinen M. BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat. 2006;27:1209–1217.
   PubMed Web of Science ®Google Scholar
• Pearl ER, Vogler LB, Okos AJ, et al. B lymphocyte precursors in human bone marrow: an analysis of normal individuals and patients with antibody-deficiency states. J Immunol. 1978;120:1169–1175.
   PubMed Web of Science ®Google Scholar
• Conley ME. B cells in patients with X-linked agammaglobulinemia. J Immunol. 1985;134:3070–3074.
   PubMed Web of Science ®Google Scholar
• Ng YS, Wardemann H, Chelnis J, et al. Bruton’s tyrosine kinase is essential for human B cell tolerance. J Exp Med. 2004;200:927–934.
   PubMed Web of Science ®Google Scholar
• Patiroglu T, Akar HH, Gunduz Z, et al. X-linked agammaglobulinemia in two siblings with a novel mutation in the BTK gene who presented with polyarticular juvenile idiopathic arthritis. Scand J Rheumatol. 2015;44:168–170.
   PubMed Web of Science ®Google Scholar
• Martin S, Wolf-Eichbaum D, Duinkerken G, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med. 2001;345:1036–1040.
   PubMed Web of Science ®Google Scholar
• Machado P, Santos A, Faria E, et al. Arthritis and X-linked agammaglobulinemia. Acta Reumatol Port. 2008;33:464–467.
   PubMed Web of Science ®Google Scholar
• Hernandez-Trujillo VP, Scalchunes C, Cunningham-Rundles C, et al. Autoimmunity and inflammation in X-linked agammaglobulinemia. J Clin Immunol. 2014;34:627–632.
   PubMed Web of Science ®Google Scholar
• Smith CI, Baskin B, Humire-Greiff P, et al. Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol. 1994;152:557–565.
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Yao L, Miura T, et al. Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon Fc epsilon RI cross-linking. Mol Cell Biol. 1994;14:5108–5113.
   PubMed Web of Science ®Google Scholar
• Lachance G, Levasseur S, Naccache PH. Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. Implication of phosphatidynositol 3-kinases. J Biol Chem. 2002;277:21537–21541.
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Inagaki N, Salek-Ardakani S, et al. Regulation of dendritic cell maturation and function by Bruton’s tyrosine kinase via IL-10 and Stat3. Proc Natl Acad Sci U S A. 2006;103:153–158.
   PubMed Web of Science ®Google Scholar
• Lougaris V, Baronio M, Vitali M, et al. Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation. J Allergy Clin Immunol. 2014;133:1644–1650 e4.
   PubMed Web of Science ®Google Scholar
• Wang J, Lau KY, Jung J, et al. Bruton’s tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells. Eur J Immunol. 2014;44:1130–1136.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Serrano ME, Estrada-Garcia I, Mogica-Martinez D, et al. Increased pro-inflammatory cytokine production after lipopolysaccharide stimulation in patients with X-linked agammaglobulinemia. J Clin Immunol. 2012;32:967–974.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhan Z, Li D, et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol. 2011;12:416–424.
   PubMed Web of Science ®Google Scholar
• Middendorp S, Dingjan GM, Hendriks RW. Impaired precursor B cell differentiation in Bruton’s tyrosine kinase-deficient mice. J Immunol. 2002;168:2695–2703.
   PubMed Web of Science ®Google Scholar
• Stadhouders R, De Bruijn MJ, Rother MB, et al. Pre-B cell receptor signaling induces immunoglobulin kappa locus accessibility by functional redistribution of enhancer-mediated chromatin interactions. PLoS Biol. 2014;12:e1001791.
   PubMed Web of Science ®Google Scholar
• Taurog JD, Moutsopoulos HM, Rosenberg YJ, et al. CBA/N X-linked B-cell defect prevents NZB B-cell hyperactivity in F1 mice. J Exp Med. 1979;150:31–43.
   PubMed Web of Science ®Google Scholar
• Cowdery JS Jr., Taurog JD, Steinberg AD. Effect of CBA/N xid on spontaneous production of antibodies to DNA in MRL/1 and NZB backcross mice. Scand J Immunol. 1980;12:499–502.
   PubMed Web of Science ®Google Scholar
• Romain PL, Cohen PL, Fish F, et al. The specific B cell subset lacking in the CBA/N mouse is not required for the production of autoantibody in (CBA/N x NZB)F1 male mice. J Immunol. 1980;125:246–251.
   PubMed Web of Science ®Google Scholar
• Taurog JD, Raveche ES, Smathers PA, et al. T cell abnormalities in NZB mice occur independently of autoantibody production. J Exp Med. 1981;153:221–234.
   PubMed Web of Science ®Google Scholar
• Smathers PA, Steinberg BJ, Reeves JP, et al. Effects of polyclonal immune stimulators upon NZB.xid congenic mice. J Immunol. 1982;128:1414–1419.
   PubMed Web of Science ®Google Scholar
• Waegell WO, Gershwin ME, Castles JJ. The use of congenital immunologic mutants to probe autoimmune disease in New Zealand mice. Prog Clin Biol Res. 1987;229:175–197.
   PubMedGoogle Scholar
• Steinberg BJ, Smathers PA, Frederiksen K, et al. Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA. J Clin Invest. 1982;70:587–597.
   PubMed Web of Science ®Google Scholar
• Steinberg EB, Santoro TJ, Chused TM, et al. Studies of congenic MRL-Ipr/Ipr.xid mice. J Immunol. 1983;131:2789–2795.
   PubMed Web of Science ®Google Scholar
• Seldin MF, Reeves JP, Scribner CL, et al. Effect of xid on autoimmune C3H-gld/gld mice. Cell Immunol. 1987;107:249–255.
   PubMed Web of Science ®Google Scholar
• Nyhoff LE, Barron B, Johnson EM, et al. Bruton’s tyrosine kinase deficiency inhibits autoimmune arthritis but fails to block immune complex-mediated inflammatory arthritis. Arthritis Rheumatol. Forthcoming 2016.
   PubMedGoogle Scholar
• Di Paolo JA, Huang T, Balazs M, et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol. 2011;7:41–50.
   PubMed Web of Science ®Google Scholar
• Chang BY, Huang MM, Francesco M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011;13:R115.
   PubMed Web of Science ®Google Scholar
• Xu D, Kim Y, Postelnek J, et al. RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J Pharmacol Exp Ther. 2012;341:90–103.
   PubMed Web of Science ®Google Scholar
• Case JB, Bonami RH, Nyhoff LE, et al. Bruton’s tyrosine kinase synergizes with Notch2 to govern marginal zone B cells in nonobese diabetic mice. J Immunol. 2015;195:61–70.
   PubMed Web of Science ®Google Scholar
• Palm A-KE, Friedrich HC, Mezger A, et al. Function and regulation of self-reactive marginal zone B cells in autoimmune arthritis. Cell Mol Immunol. 2015;12:493–504.
   PubMed Web of Science ®Google Scholar
• Satterthwaite AB, Lowell CA, Khan WN, et al. Independent and opposing roles for Btk and lyn in B and myeloid signaling pathways. J Exp Med. 1998;188:833–844.
   PubMed Web of Science ®Google Scholar
• Takeshita H, Taniuchi I, Kato J, et al. Abrogation of autoimmune disease in Lyn-deficient mice by the mutation of the Btk gene. Int Immunol. 1998;10:435–444.
   PubMed Web of Science ®Google Scholar
• Svensson L, Abdul-Majid KB, Bauer J, et al. A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination. Eur J Immunol. 2002;32:1939–1946.
   PubMed Web of Science ®Google Scholar
• Mangla A, Khare A, Vineeth V, et al. Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood. 2004;104:1191–1197.
   PubMed Web of Science ®Google Scholar
• Mahajan S, Ghosh S, Sudbeck EA, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton’s tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem. 1999;274:9587–9599.
   PubMed Web of Science ®Google Scholar
• Rushworth SA, MacEwan DJ, Bowles KM. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:1277–1278.
   PubMed Web of Science ®Google Scholar
• Akinleye A, Chen Y, Mukhi N, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013;6:59.
   PubMed Web of Science ®Google Scholar
• Evans EK, Tester R, Aslanian S, et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013;346:219–228.
   PubMed Web of Science ®Google Scholar
• Robak T, Robak E. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin Investig Drugs. 2012;21:921–947.
   PubMed Web of Science ®Google Scholar
• Dias AL, Jain D. Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton’s tyrosine kinase inhibition. Cardiovasc Hematol Agents Med Chem. 2013;11:265–271.
   PubMedGoogle Scholar
• Vargas L, Hamasy A, Nore BF, et al. Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases. Scand J Immunol. 2013;78:130–139.
   PubMed Web of Science ®Google Scholar
• Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. Chem Med Chem. 2007;2:58–61.
   Web of Science ®Google Scholar
• Cameron F, Sanford M. Ibrutinib: first global approval. Drugs. 2014;74:263–271.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Kapoor P, Ansell SM, et al. Ibrutinib for the treatment of Waldenstrom macroglobulinemia. Expert Rev Hematol. 2015;8:569–579.
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539–2549.
   PubMed Web of Science ®Google Scholar
• Lou Y, Han X, Kuglstatter A, et al. Structure-based drug design of RN486, a potent and selective Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis. J Med Chem. 2015;58:512–516.
   PubMed Web of Science ®Google Scholar
• Cetkovic-Cvrlje M, Uckun FM. Dual targeting of Bruton’s tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model. Br J Haematol. 2004;126:821–827.
   PubMed Web of Science ®Google Scholar
• Ruderman EM, Pope RM. More than just B-cell inhibition. Arthritis Res Ther. 2011;13:125.
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107:13075–13080.
   PubMed Web of Science ®Google Scholar
• Liu L, Di Paolo J, Barbosa J, et al. Antiarthritis effect of a novel Bruton’s tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol Exp Ther. 2011;338:154–163.
   PubMed Web of Science ®Google Scholar
• Hutcheson J, Vanarsa K, Bashmakov A, et al. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. Arthritis Res Ther. 2012;14:R243.
   PubMed Web of Science ®Google Scholar
• Rankin AL, Seth N, Keegan S, et al. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. J Immunol. 2013;191:4540–4550.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48–58.
   PubMed Web of Science ®Google Scholar
• Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126:2213–2219.
   PubMed Web of Science ®Google Scholar
• Rogers KA, Ruppert AS, Bingman A, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2016;30:346–350.
   PubMed Web of Science ®Google Scholar
• Tipton CM, Fucile CF, Darce J, et al. Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat Immunol. 2015;16:755–765.
   PubMed Web of Science ®Google Scholar
• de Gorter DJJ, Beuling EA, Kersseboom R, et al. Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity. 2007;26:93–104.
   PubMed Web of Science ®Google Scholar
• Chang BY, Francesco M, De Rooij MFM, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013;122:2412–2424.
   PubMed Web of Science ®Google Scholar
• Finch DK, Ettinger R, Karnell JL, et al. Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease. Eur J Clin Invest. 2013;43:501–509.
   PubMed Web of Science ®Google Scholar
• Klimatcheva E, Pandina T, Reilly C, et al. CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol. 2015;16:6.
   PubMed Web of Science ®Google Scholar
• Henry RA, Kendall PL. CXCL13 blockade disrupts B lymphocyte organization in tertiary lymphoid structures without altering B cell receptor bias or preventing diabetes in nonobese diabetic mice. J Immunol. 2010;185:1460–1465.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286–2294.
   PubMed Web of Science ®Google Scholar
• Furman RR, Cheng S, Lu P, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014;370:2352–2354.
   PubMed Web of Science ®Google Scholar
• Liu TM, Woyach JA, Zhong Y, et al. Hypermorphic mutation of phospholipase C, gamma2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood. 2015;126:61–68.
   PubMed Web of Science ®Google Scholar
• Cheng S, Guo A, Lu P, et al. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia. 2015;29:895–900.
   PubMed Web of Science ®Google Scholar